

NewLink Genetics Corporation Investor Relations Department 2503 South Loop Drive Ames, IA 50010 United States

Visit IR website ☐ Sign-up for Email alerts ☐

## **Company Profile**

Founded in 1999, NewLink Genetics is an immuno-oncology company focused on discovering and developing novel products for the treatment of cancer. The drug discovery and development teams at NewLink Genetics are relentlessly pursuing a wide range of immuno-oncology portfolio candidates with the potential to change the oncology landscape. NewLink Genetics' portfolio includes two small-molecule product candidates currently in clinical development. These product candidates inhibit the IDO pathway, a key immuno-oncology target, and focus on breaking the immune system's tolerance to cancer.

## Press Releases [View all]

Jul 10, 2017

NewLink Genetics Receives Notice of Allowance from USPTO Covering Indoximod Salts and Prodrugs

Jul 7, 2017

NewLink Genetics to Host Its Second
Quarter 2017 Financial Results Conference
Call on July 28, 2017

Jun 23, 2017

Positive Phase 1b Data for NewLink
Genetics' IDO Pathway Inhibitor,
Indoximod, in Combination with
Chemotherapy for Patients with Newly
Diagnosed Acute Myeloid Leukemia (AML)
Presented at the European Hematologic
Association (EHA) Congress in Madrid,
Spain

Jun 8, 2017

NewLink Genetics to Regain Rights to GDC-0919

Jun 5. 2017

NewLink Genetics' Indoximod +
PROVENGE® Results in Statistically
Significant Improvement in Radiographic
Progression-Free Survival (rPFS) for
Patients with Metastatic Castration
Resistant Prostate Cancer (mCRPC) in
Phase 2 Trial

## Upcoming Events [View all]

Jul 28, 2017 8:30 AM ET
Second Quarter 2017 Earnings Conference
Call

Financials [View all]

First Quarter Financial Results

Mar 6, 2017

Annual Report (10-K)

Mar 31, 2017

Proxy Statement (DEF 14A)

May 5, 2017

Quarterly Report (10-Q)

Nov 8, 2016

Quarterly Report (10-Q)

Aug 5, 2016

Quarterly Report (10-Q)